Improving treatment response in aggressive endometrial cancer by inhibiting AXL
Official title: Project 2: Inhibiting AXL to Improve Treatment Response in Endometrial Cancer
Funded at Washington University · NIH-10912618 · Data updated 2026-11-12
This study is looking at how well a new drug called batiraxcept works with a common chemotherapy drug, paclitaxel, to help people with aggressive types of endometrial cancer, and it aims to find out if this combination is safe and if certain markers can help predict how well patients will respond to the treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | August 23, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $413,218 |
| NIH project number | 5P50CA265793-02 |
| Project ID | NIH-10912618 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with recurrent uterine serous cancer or grade 3 endometrioid endometrial cancer.
✕Less likely to help
Patients with early-stage endometrial cancer or those not diagnosed with aggressive histologies may not benefit from this research.
What this research studies
This research investigates the potential of a drug called batiraxcept to enhance the effectiveness of standard treatments for aggressive forms of endometrial cancer, specifically uterine serous cancer and high-grade endometrioid tumors. The study aims to determine the safety and tolerability of combining batiraxcept with paclitaxel, a common chemotherapy drug, while also identifying biomarkers that may predict treatment response. By targeting the AXL pathway, which is linked to poor survival rates in these cancers, the research seeks to improve patient outcomes through a more personalized treatment approach.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment responses and survival rates for patients with aggressive endometrial cancer.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting the AXL pathway in other cancer types, suggesting potential for success in this context.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Mutch, David G — Washington University
- Study coordinator: Mutch, David G
Related research
Other NIH-funded projects on the same topics.
-
Prognostic tools to guide adjuvant therapy for Black women after hysterectomy for endometrial cancer
A new project aims to create and validate easy-to-use tools that help doctors tailor post-surgery treatment for Black women with endometrial cancer.
-
Understanding why guideline-concordant endometrial cancer treatment varies in high-risk groups
This project looks at why some patients with endometrial cancer don’t receive care that follows national guidelines, aiming to find ways to ensure more patients get the best-supported treatments.
-
Targeting hormone resistance to prevent endometrial cancer
Aims to boost progesterone’s cancer-preventing effect in the lining of the uterus to stop cancer from developing in people at risk, especially those who are obese or young.
-
Inhibiting AXL to Improve Treatment Response in Endometrial Cancer
A cancer treatment study is testing whether blocking AXL with batiraxcept together with standard chemotherapy can help people with certain aggressive uterine cancers respond better.
-
Targeting HSPA Proteins to Help Women with Advanced or Recurrent Endometrial Cancer
Aims to test a drug called SHetA2 that may slow or stop growth of advanced endometrial cancer by targeting cancer-friendlier proteins, with a focus on reducing treatment toxicity.
-
Endometrial Cancer SPORE: New strategies to prevent and treat endometrial cancer
A multi-institution program is testing new ways to prevent and treat endometrial cancer in people, with three linked projects and multiple cores to support translational research.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.